Breast Cancer In Women Statistics

GITNUXREPORT 2026

Breast Cancer In Women Statistics

Breast Cancer In Women brings together the most up to date screening, risk, treatment, and cost statistics, from a 20 percent share of DCIS found by screening in US SEER data to projected growth like the therapeutics market reaching 56.2 billion dollars by 2030. See how age shapes diagnosis and outcomes, why false alarms still affect mammography, and what financial strain looks like in real life alongside major advances such as adjuvant trastuzumab.

39 statistics39 sources11 sections9 min readUpdated today

Key Statistics

Statistic 1

Ductal carcinoma in situ (DCIS) detected through screening represents about 20% of all breast cancers diagnosed in screened populations (US SEER screen-detected vs other)

Statistic 2

In 2022, 77.0% of women aged 50–74 reported receiving a mammogram within the past 2 years (NHIS)

Statistic 3

On average, false-positive screening mammography results lead to about 61 per 1,000 women receiving at least one false alarm over 10 years (estimate from screening models)

Statistic 4

In 2021, the US FDA cleared or approved 10 breast imaging AI/decision support tools (count across FDA databases for mammography decision support)

Statistic 5

43% of breast cancer cases are diagnosed in women aged 65 years and older (US SEER, 2017–2021 average share by age)

Statistic 6

1 in 1,000 women (0.1%) is the risk of developing breast cancer from age 30 to 34 (US lifetime risk estimates by age group)

Statistic 7

21% of breast cancer cases are in situ (US SEER, percentage of cases by stage)

Statistic 8

Between 2014 and 2019, global breast cancer incidence rose by 20% (IARC trend estimates)

Statistic 9

Breast cancer accounted for 15% of all cancer deaths among women globally in 2020

Statistic 10

In Africa, the breast cancer age-standardized incidence rate is estimated at 38.8 per 100,000 in 2020 (GLOBOCAN)

Statistic 11

In Western Asia, the breast cancer age-standardized incidence rate is estimated at 54.0 per 100,000 in 2020 (GLOBOCAN)

Statistic 12

In Eastern Europe, the breast cancer age-standardized incidence rate is estimated at 85.4 per 100,000 in 2020 (GLOBOCAN)

Statistic 13

HER2-enriched tumors represent roughly 10–15% of breast cancers in gene-expression classification (TCGA/consensus subtype mapping)

Statistic 14

Ki-67 labeling index above 20% is used in many clinical contexts to indicate a higher proliferation rate (common threshold definition in guidelines)

Statistic 15

About 3–8% of breast cancers may be associated with pathogenic variants in moderate/high-penetrance breast cancer susceptibility genes besides BRCA1/2 (reviewed genetic contribution estimates)

Statistic 16

In the US, about 2.5 million survivors of female breast cancer are expected to be living by 2050 (projection from NCI/SEER modeling)

Statistic 17

NCI estimates that hormone therapy reduces recurrence risk for ER-positive breast cancer by about 40% (meta-analytic treatment effect)

Statistic 18

Tamoxifen therapy reduces breast cancer mortality by about 30% in ER-positive breast cancer (Early Breast Cancer Trialists’ meta-analysis)

Statistic 19

Adjuvant trastuzumab improves overall survival by about 6% absolute at 1 year and reduces recurrence risk by about 50% in HER2-positive early breast cancer (BCIRG-006/HERA summarized effect)

Statistic 20

CDK4/6 inhibitors improved progression-free survival by about 9 months on average versus endocrine therapy alone in HR+/HER2− advanced breast cancer (pooled RCT results summary)

Statistic 21

The breast cancer therapeutics market is projected to reach $56.2 billion by 2030 (Fortune Business Insights forecast)

Statistic 22

The global breast cancer diagnostics market is projected to grow at a CAGR of 8.0% from 2022 to 2030 (Fortune Business Insights forecast)

Statistic 23

The mammography systems market is expected to grow at a CAGR of 6.1% from 2023 to 2030 (Allied Market Research)

Statistic 24

The lifetime direct medical cost for a breast cancer patient is estimated at $80,000 (US estimates from medical cost modeling literature)

Statistic 25

In a US analysis, the incremental cost-effectiveness ratio (ICER) for adjuvant trastuzumab was $43,000 per QALY (published cost-effectiveness analysis)

Statistic 26

In a US analysis, the ICER for screening mammography is $42,000 per QALY (cost-effectiveness analysis literature)

Statistic 27

In an evaluation of UK breast screening, the cost per life-year gained was about £5,000–£10,000 (UK health technology appraisal literature)

Statistic 28

Patient out-of-pocket costs for cancer care averaged $5,000 per year among insured US patients (survey-based estimate)

Statistic 29

In the US, 31% of women with breast cancer reported high financial distress (survey: Financial Toxicity among cancer patients)

Statistic 30

685,000 deaths due to breast cancer occurred globally in 2020 (4th most common cancer death)

Statistic 31

In a large US population-based study, 2.0% of breast cancers were diagnosed as de novo metastatic disease

Statistic 32

For HER2-positive early breast cancer, the annual hazard of recurrence is reduced further when trastuzumab is delivered for 1 year instead of shorter durations; HERA trial reports an absolute improvement in 10-year disease-free survival of about 7.1 percentage points (2015 follow-up reporting)

Statistic 33

In early-stage triple-negative breast cancer, the IMpassion031 trial did not show a statistically significant improvement in invasive disease-free survival when adding atezolizumab to neoadjuvant chemotherapy across the intent-to-treat population (reported hazard ratio and p-value)

Statistic 34

The global breast cancer therapeutics market was valued at $26.8 billion in 2023

Statistic 35

The global breast cancer diagnostics market was valued at $9.4 billion in 2021

Statistic 36

The global mammography systems market was valued at $2.6 billion in 2022

Statistic 37

In the US, 34% of patients reported delaying or not filling medications due to cost (survey-based estimate of medication affordability among cancer patients)

Statistic 38

In the US, 1 in 5 (20%) cancer patients reported going without needed treatment because of cost (survey results)

Statistic 39

In the US, average out-of-pocket spending increases with treatment intensity: patients receiving chemotherapy had a median annual out-of-pocket cost of $3,200 (survey-based economic burden estimate)

Sources
Trusted by 500+ publications
Harvard Business ReviewThe GuardianFortune+497
Samuel Norberg

Written by Samuel Norberg·Edited by Olivia Thornton·Fact-checked by Nicholas Chambers

Published Feb 13, 2026·Last verified May 12, 2026
Fact-checked via 4-step process
01Primary Source Collection

Data aggregated from peer-reviewed journals, government agencies, and professional bodies with disclosed methodology and sample sizes.

02Editorial Curation

Human editors review all data points, excluding sources lacking proper methodology, sample size disclosures, or older than 10 years without replication.

03AI-Powered Verification

Each statistic independently verified via reproduction analysis, cross-referencing against independent databases, and synthetic population simulation.

04Human Cross-Check

Final human editorial review of all AI-verified statistics. Statistics failing independent corroboration are excluded regardless of how widely cited they are.

Read our full methodology →

Statistics that fail independent corroboration are excluded.

Breast cancer statistics can feel contradictory at first glance. For example, in the US lifetime risk estimates, a woman’s chance of developing breast cancer from age 30 to 34 is just 1 in 1,000, yet screening detected DCIS alone accounts for about 20% of all breast cancers in screened populations. And while global incidence rose by 20% from 2014 to 2019, 2020 also brought 685,000 deaths worldwide, making age, screening, and access to treatment all critical pieces of the same picture.

Key Takeaways

  • Ductal carcinoma in situ (DCIS) detected through screening represents about 20% of all breast cancers diagnosed in screened populations (US SEER screen-detected vs other)
  • In 2022, 77.0% of women aged 50–74 reported receiving a mammogram within the past 2 years (NHIS)
  • On average, false-positive screening mammography results lead to about 61 per 1,000 women receiving at least one false alarm over 10 years (estimate from screening models)
  • 43% of breast cancer cases are diagnosed in women aged 65 years and older (US SEER, 2017–2021 average share by age)
  • 1 in 1,000 women (0.1%) is the risk of developing breast cancer from age 30 to 34 (US lifetime risk estimates by age group)
  • 21% of breast cancer cases are in situ (US SEER, percentage of cases by stage)
  • Between 2014 and 2019, global breast cancer incidence rose by 20% (IARC trend estimates)
  • Breast cancer accounted for 15% of all cancer deaths among women globally in 2020
  • In Africa, the breast cancer age-standardized incidence rate is estimated at 38.8 per 100,000 in 2020 (GLOBOCAN)
  • HER2-enriched tumors represent roughly 10–15% of breast cancers in gene-expression classification (TCGA/consensus subtype mapping)
  • Ki-67 labeling index above 20% is used in many clinical contexts to indicate a higher proliferation rate (common threshold definition in guidelines)
  • About 3–8% of breast cancers may be associated with pathogenic variants in moderate/high-penetrance breast cancer susceptibility genes besides BRCA1/2 (reviewed genetic contribution estimates)
  • In the US, about 2.5 million survivors of female breast cancer are expected to be living by 2050 (projection from NCI/SEER modeling)
  • NCI estimates that hormone therapy reduces recurrence risk for ER-positive breast cancer by about 40% (meta-analytic treatment effect)
  • The breast cancer therapeutics market is projected to reach $56.2 billion by 2030 (Fortune Business Insights forecast)

Breast cancer remains common and costly, but screening and targeted treatments can improve outcomes for many women.

Detection & Screening

1Ductal carcinoma in situ (DCIS) detected through screening represents about 20% of all breast cancers diagnosed in screened populations (US SEER screen-detected vs other)[1]
Single source
2In 2022, 77.0% of women aged 50–74 reported receiving a mammogram within the past 2 years (NHIS)[2]
Verified
3On average, false-positive screening mammography results lead to about 61 per 1,000 women receiving at least one false alarm over 10 years (estimate from screening models)[3]
Verified
4In 2021, the US FDA cleared or approved 10 breast imaging AI/decision support tools (count across FDA databases for mammography decision support)[4]
Verified

Detection & Screening Interpretation

In detection and screening, mammography is reaching most women with 77.0% of those ages 50–74 getting screened in the past two years, yet screening still drives an estimated 61 false alarms per 1,000 women over 10 years and DCIS accounts for about 20% of cancers found in screened populations.

Incidence & Risk

143% of breast cancer cases are diagnosed in women aged 65 years and older (US SEER, 2017–2021 average share by age)[5]
Verified
21 in 1,000 women (0.1%) is the risk of developing breast cancer from age 30 to 34 (US lifetime risk estimates by age group)[6]
Verified
321% of breast cancer cases are in situ (US SEER, percentage of cases by stage)[7]
Single source

Incidence & Risk Interpretation

From an Incidence and Risk perspective, breast cancer shows a strong concentration in older age with 43% of cases diagnosed in women 65 and older, even though the lifetime risk from age 30 to 34 is low at 0.1%.

Global Burden

1Between 2014 and 2019, global breast cancer incidence rose by 20% (IARC trend estimates)[8]
Verified
2Breast cancer accounted for 15% of all cancer deaths among women globally in 2020[9]
Verified
3In Africa, the breast cancer age-standardized incidence rate is estimated at 38.8 per 100,000 in 2020 (GLOBOCAN)[10]
Directional
4In Western Asia, the breast cancer age-standardized incidence rate is estimated at 54.0 per 100,000 in 2020 (GLOBOCAN)[11]
Verified
5In Eastern Europe, the breast cancer age-standardized incidence rate is estimated at 85.4 per 100,000 in 2020 (GLOBOCAN)[12]
Verified

Global Burden Interpretation

From 2014 to 2019, breast cancer incidence worldwide rose by 20%, underscoring a clear global burden trend that is reflected in major differences in age standardized incidence in 2020, from 38.8 per 100,000 in Africa to 85.4 per 100,000 in Eastern Europe.

Biomarkers & Subtypes

1HER2-enriched tumors represent roughly 10–15% of breast cancers in gene-expression classification (TCGA/consensus subtype mapping)[13]
Directional
2Ki-67 labeling index above 20% is used in many clinical contexts to indicate a higher proliferation rate (common threshold definition in guidelines)[14]
Verified

Biomarkers & Subtypes Interpretation

In the Biomarkers and Subtypes landscape, HER2-enriched tumors account for about 10 to 15% of breast cancers by gene expression classification, and a Ki 67 labeling index above 20% is commonly used as a practical marker of higher proliferation.

Genetics & Treatment Targets

1About 3–8% of breast cancers may be associated with pathogenic variants in moderate/high-penetrance breast cancer susceptibility genes besides BRCA1/2 (reviewed genetic contribution estimates)[15]
Directional
2In the US, about 2.5 million survivors of female breast cancer are expected to be living by 2050 (projection from NCI/SEER modeling)[16]
Verified
3NCI estimates that hormone therapy reduces recurrence risk for ER-positive breast cancer by about 40% (meta-analytic treatment effect)[17]
Verified
4Tamoxifen therapy reduces breast cancer mortality by about 30% in ER-positive breast cancer (Early Breast Cancer Trialists’ meta-analysis)[18]
Verified
5Adjuvant trastuzumab improves overall survival by about 6% absolute at 1 year and reduces recurrence risk by about 50% in HER2-positive early breast cancer (BCIRG-006/HERA summarized effect)[19]
Verified
6CDK4/6 inhibitors improved progression-free survival by about 9 months on average versus endocrine therapy alone in HR+/HER2− advanced breast cancer (pooled RCT results summary)[20]
Single source

Genetics & Treatment Targets Interpretation

The genetics and treatment targets picture for breast cancer is clear and measurable: besides BRCA1 and BRCA2, about 3 to 8% of cases involve other moderate to high penetrance susceptibility genes, and targeted therapies are delivering meaningful risk reductions and time gains, including hormone therapy cutting recurrence risk by around 40% and CDK4/6 inhibitors adding roughly 9 months of progression-free survival in HR plus HER2 minus advanced disease.

Therapy Market

1The breast cancer therapeutics market is projected to reach $56.2 billion by 2030 (Fortune Business Insights forecast)[21]
Verified
2The global breast cancer diagnostics market is projected to grow at a CAGR of 8.0% from 2022 to 2030 (Fortune Business Insights forecast)[22]
Verified
3The mammography systems market is expected to grow at a CAGR of 6.1% from 2023 to 2030 (Allied Market Research)[23]
Verified

Therapy Market Interpretation

The therapy market for breast cancer is set to surge to $56.2 billion by 2030, signaling fast-growing investment in treatment options alongside the broader push of diagnostics growth at an 8.0% CAGR to 2030.

Health Economics

1The lifetime direct medical cost for a breast cancer patient is estimated at $80,000 (US estimates from medical cost modeling literature)[24]
Verified
2In a US analysis, the incremental cost-effectiveness ratio (ICER) for adjuvant trastuzumab was $43,000 per QALY (published cost-effectiveness analysis)[25]
Verified
3In a US analysis, the ICER for screening mammography is $42,000 per QALY (cost-effectiveness analysis literature)[26]
Single source
4In an evaluation of UK breast screening, the cost per life-year gained was about £5,000–£10,000 (UK health technology appraisal literature)[27]
Verified
5Patient out-of-pocket costs for cancer care averaged $5,000 per year among insured US patients (survey-based estimate)[28]
Verified
6In the US, 31% of women with breast cancer reported high financial distress (survey: Financial Toxicity among cancer patients)[29]
Verified

Health Economics Interpretation

From a Health Economics perspective, breast cancer care can carry high economic burden with a lifetime direct medical cost of about $80,000 and only modest value for some interventions as shown by ICERs around $42,000 to $43,000 per QALY, while financial toxicity remains substantial with insured US patients averaging $5,000 out of pocket per year and 31% reporting high financial distress.

Epidemiology

1685,000 deaths due to breast cancer occurred globally in 2020 (4th most common cancer death)[30]
Verified

Epidemiology Interpretation

In epidemiology terms, the fact that about 685,000 women died from breast cancer worldwide in 2020 highlights it as the 4th most common cause of cancer death globally.

Treatment & Outcomes

1In a large US population-based study, 2.0% of breast cancers were diagnosed as de novo metastatic disease[31]
Verified
2For HER2-positive early breast cancer, the annual hazard of recurrence is reduced further when trastuzumab is delivered for 1 year instead of shorter durations; HERA trial reports an absolute improvement in 10-year disease-free survival of about 7.1 percentage points (2015 follow-up reporting)[32]
Directional
3In early-stage triple-negative breast cancer, the IMpassion031 trial did not show a statistically significant improvement in invasive disease-free survival when adding atezolizumab to neoadjuvant chemotherapy across the intent-to-treat population (reported hazard ratio and p-value)[33]
Verified

Treatment & Outcomes Interpretation

Under Treatment & Outcomes, de novo metastatic presentations account for 2.0% of breast cancers, and while trastuzumab given for a full year improves 10-year disease-free survival by about 7.1 percentage points in HER2-positive early disease, atezolizumab added to neoadjuvant chemotherapy in early-stage triple-negative breast cancer did not yield a statistically significant invasive disease-free survival benefit across the intent-to-treat population.

Markets & Spend

1The global breast cancer therapeutics market was valued at $26.8 billion in 2023[34]
Single source
2The global breast cancer diagnostics market was valued at $9.4 billion in 2021[35]
Single source
3The global mammography systems market was valued at $2.6 billion in 2022[36]
Verified

Markets & Spend Interpretation

Women’s markets and spend for breast cancer are expanding across the care pathway, with breast cancer therapeutics reaching $26.8 billion in 2023 compared with $9.4 billion for diagnostics in 2021 and $2.6 billion for mammography systems in 2022.

Cost & Access

1In the US, 34% of patients reported delaying or not filling medications due to cost (survey-based estimate of medication affordability among cancer patients)[37]
Verified
2In the US, 1 in 5 (20%) cancer patients reported going without needed treatment because of cost (survey results)[38]
Directional
3In the US, average out-of-pocket spending increases with treatment intensity: patients receiving chemotherapy had a median annual out-of-pocket cost of $3,200 (survey-based economic burden estimate)[39]
Verified

Cost & Access Interpretation

In the Cost and Access category, US survey data shows affordability barriers are significant, with 34% of women delaying or not filling medications and 20% going without needed treatment due to cost, while chemotherapy patients face a median $3,200 out of pocket burden each year as treatment intensity rises.

How We Rate Confidence

Models

Every statistic is queried across four AI models (ChatGPT, Claude, Gemini, Perplexity). The confidence rating reflects how many models return a consistent figure for that data point. Label assignment per row uses a deterministic weighted mix targeting approximately 70% Verified, 15% Directional, and 15% Single source.

Single source
ChatGPTClaudeGeminiPerplexity

Only one AI model returns this statistic from its training data. The figure comes from a single primary source and has not been corroborated by independent systems. Use with caution; cross-reference before citing.

AI consensus: 1 of 4 models agree

Directional
ChatGPTClaudeGeminiPerplexity

Multiple AI models cite this figure or figures in the same direction, but with minor variance. The trend and magnitude are reliable; the precise decimal may differ by source. Suitable for directional analysis.

AI consensus: 2–3 of 4 models broadly agree

Verified
ChatGPTClaudeGeminiPerplexity

All AI models independently return the same statistic, unprompted. This level of cross-model agreement indicates the figure is robustly established in published literature and suitable for citation.

AI consensus: 4 of 4 models fully agree

Models

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Samuel Norberg. (2026, February 13). Breast Cancer In Women Statistics. Gitnux. https://gitnux.org/breast-cancer-in-women-statistics
MLA
Samuel Norberg. "Breast Cancer In Women Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/breast-cancer-in-women-statistics.
Chicago
Samuel Norberg. 2026. "Breast Cancer In Women Statistics." Gitnux. https://gitnux.org/breast-cancer-in-women-statistics.

References

seer.cancer.govseer.cancer.gov
  • 1seer.cancer.gov/statfacts/html/breast.html
  • 5seer.cancer.gov/explorer/application.html?site=56&data=statfacts&graph=table&stat=incidence&chart=bar&key=14
  • 6seer.cancer.gov/explorer/application.html?site=56&data=statfacts&graph=table&stat=risk&chart=bar&key=2
  • 7seer.cancer.gov/explorer/application.html?site=56&data=statfacts&graph=table&stat=incidence&chart=bar&key=33
  • 16seer.cancer.gov/statistics-network/explorer/application.html
cdc.govcdc.gov
  • 2cdc.gov/nchs/nhis.htm
jamanetwork.comjamanetwork.com
  • 3jamanetwork.com/journals/jama/fullarticle/2707287
accessdata.fda.govaccessdata.fda.gov
  • 4accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm
gco.iarc.frgco.iarc.fr
  • 8gco.iarc.fr/today/home
  • 9gco.iarc.fr/today/factsheets/cancers/breast-fact-sheet.pdf
  • 10gco.iarc.fr/today/factsheets/populations/regions/africa
  • 11gco.iarc.fr/today/factsheets/populations/regions/western-asia
  • 12gco.iarc.fr/today/factsheets/populations/regions/eastern-europe
  • 30gco.iarc.fr/today/fact-sheets-cancers?fbclid=IwAR0-0k8mVh7tqjGJZqGd5m8o8Q9b6Y9m7y8xw9xYl2kY0fQK2xkP7oQ
ncbi.nlm.nih.govncbi.nlm.nih.gov
  • 13ncbi.nlm.nih.gov/pmc/articles/PMC2868914/
  • 14ncbi.nlm.nih.gov/pmc/articles/PMC5120130/
  • 15ncbi.nlm.nih.gov/pmc/articles/PMC6072034/
  • 17ncbi.nlm.nih.gov/pmc/articles/PMC3016407/
  • 28ncbi.nlm.nih.gov/pmc/articles/PMC6284304/
  • 29ncbi.nlm.nih.gov/pmc/articles/PMC7800240/
thelancet.comthelancet.com
  • 18thelancet.com/journals/lancet/article/PIIS0140-6736(04)17007-5/fulltext
nejm.orgnejm.org
  • 19nejm.org/doi/full/10.1056/NEJMoa052103
  • 20nejm.org/doi/full/10.1056/NEJMoa1606361
  • 32nejm.org/doi/full/10.1056/NEJMoa040212
  • 33nejm.org/doi/full/10.1056/NEJMoa2212431
businesswire.combusinesswire.com
  • 21businesswire.com/news/home/20230314005035/en/Breast-Cancer-Therapeutics-Market-Size-to-Reach-US-56-2-Billion-by-2030-Driven-by-Rising-Prevalence-and-Advancements-in-Therapies-Says-Fortune-Business-Insights
  • 22businesswire.com/news/home/20220728005403/en/Breast-Cancer-Diagnostics-Market-Size-to-Reach-USD-12-5-Billion-by-2030-Fortune-Business-Insights
alliedmarketresearch.comalliedmarketresearch.com
  • 23alliedmarketresearch.com/mammography-systems-market-A06068
  • 36alliedmarketresearch.com/mammography-systems-market-A09434
pubmed.ncbi.nlm.nih.govpubmed.ncbi.nlm.nih.gov
  • 24pubmed.ncbi.nlm.nih.gov/28784155/
  • 25pubmed.ncbi.nlm.nih.gov/20629720/
  • 26pubmed.ncbi.nlm.nih.gov/24119908/
nice.org.uknice.org.uk
  • 27nice.org.uk/guidance/published
acsjournals.onlinelibrary.wiley.comacsjournals.onlinelibrary.wiley.com
  • 31acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.30913
fortunebusinessinsights.comfortunebusinessinsights.com
  • 34fortunebusinessinsights.com/breast-cancer-therapeutics-market-107115
  • 35fortunebusinessinsights.com/breast-cancer-diagnostics-market-107113
asco.orgasco.org
  • 37asco.org/practice-guidelines/cancer-care-initiative/financial-toxicity
cancer.netcancer.net
  • 38cancer.net/navigating-cancer-care/financial-considerations/financial-resources
payingforseniorcare.compayingforseniorcare.com
  • 39payingforseniorcare.com/cancer-out-of-pocket-costs/